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COMMENTARY
Crosslinked clots formed independently of factor XIII and
without fibrinogen-to-fibrin conversion – is this a
liver-specific phenomenon?
T . L I SMAN
Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen,
University Medical Center Groningen, Groningen, the Netherlands
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See also Poole LG, Pant A, Baker KS, Kopec AK, Cline-Fedewa HM, Iismaa SE, Flick MJ, Luyendyk JP. Chronic liver injury drives non-traditional
intrahepatic fibrin(ogen) cross-linking via tissue transglutaminase. J Thromb Haemost 2018; https://doi.org/10.1111/jth.14330.
Both basic and applied studies dealing with aspects of
hemostasis in patients with liver diseases have spurred sig-
nificant controversy over the last two decades [1]. Clini-
cally, we have learnt that patients with liver diseases do
not necessarily have a hemostatic defect resulting in a
bleeding tendency. Instead, these patients appear to be in
hemostatic balance, owing to declines in both prohemo-
static and antihemostatic pathways, and may experience
both bleeding and thrombotic complications when this
reset hemostatic balance is offset [2]. These insights into
the hemostatic status of these patients have led to the
realization that correction of hemostasis before interven-
tional procedures is frequently not required, and can even
do harm. Major procedures, notably liver transplantation,
can be performed in patients with profound ‘coagulopa-
thy’ (defined as thrombocytopenia and/or prolongations
in the prothrombin time) without the requirement for any
prohemostatic interventions [3]. Not all proceduralists,
however, accept the change in dogma, and require correc-
tion of hemostasis prior to minor invasive procedures
with an established low bleeding risk. Despite overwhelm-
ing clinical and laboratory evidence arguing against cor-
rection of the prothrombin time prior to invasive
procedures in patients with chronic liver disease [4], some
guidelines specifically state that correction should be
performed [5]. In organized attempts to convince proce-
duralists and professional organizations, my colleagues
and I have frequently heard ‘Are you telling me that
everything I have been taught in medical school was
wrong?’ Obviously, this is not the case, as tests such as
the prothrombin time were never designed to predict
(procedural) bleeding, but, unfortunately, they have been
used as such. Acceptance of changes in dogma is some-
times slow.
In this issue of the Journal of Thrombosis and Haemosta-
sis, Poole et al. present data that made me wonder whether
everything I have been taught in the 20 years in which I
have studied thrombosis and hemostasis is wrong [6]. In a
mouse model of chronic liver injury, it was demonstrated
that crosslinked fibrin(ogen) is deposited in a process that
does not require fibrinogen-to-fibrin conversion or fac-
tor XIII. Rather, these ‘non-traditional’ clots can be
formed from fibrinogen that is crosslinked by tissue transg-
lutaminase (TG2), which is a multifunctional and widely
expressed protein that has been implicated in diabetes and
celiac disease, and as a player in inflammation, apoptosis,
and matrix remodeling [7]. Although TG2 is known to
crosslink fibrin(ogen) in vitro [8], this study is the first to
document TG2-dependent fibrin(ogen) crosslinking in vivo.
Interestingly, intrahepatic deposition of non-traditional
fibrin(ogen) had no effect on the severity of disease in this
model, and this challenges a second dogma in the field of
hemostasis and liver diseases. This study provides the first
evidence that the beneficial effects of anticoagulants in
delaying the progression of liver disease in animals and
humans probably result from inhibition of thrombin
rather than inhibition of fibrin formation, and therefore
argues against the theory of ‘parenchymal extinction’, i.e.
microthrombosis caused by intrahepatic clot formation,
as the driver of progression of chronic liver disease [9,10].
The two seminal findings from this study – crosslinked
clots can be formed without thrombin-mediated
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fibrinogen-to-fibrin conversion, without the requirement
for activated FXIII (FXIIIa) activity, and intrahepatic fib-
rin(ogen) deposition does not alter the progression of
chronic liver disease, give rise to a wide array of questions.
1 Are these ‘non-traditional’ fibrinogen clots also formed
in humans? As TG2-crosslinked fibrinogen has unique
structural characteristics (i.e. specific a–c hybrid cross-
links) [8], examination of fibrin(ogen) structures in, for
example, biopsies of human diseased liver, or in human
vascular clots (see below), should be possible. In fact, it
was already stated in an article published in 1991 that
‘Thus, whenever a tissue transglutaminase might escape
from cells into the plasma environment where it could
directly interact with fibrinogen . . . diagnostic analysis
should include a search for this internally crosslinked
monomeric form of fibrinogen’ [11], but, to my knowl-
edge, this proposal was never followed up.
2 Are these clots truly ‘clots’ or are they, for example,
thin ‘sheets’ of crosslinked fibrinogen that are attached
to collagen, as suggested by the authors? The shape
and localization of intrahepatic fibrin(ogen) have not
been extensively explored, and more in-depth (electron)
microscopy studies are urgently needed to provide a
better understanding of the nature of these fibrin(ogen)
structures that have only been identified with immuno-
histochemical labeling of liver sections [12].
3 What initiates intrahepatic fibrinogen deposition? If intra-
hepatic activation of coagulation is not required as such,
what signals are required for fibrinogen deposition and
TG2-mediated crosslinking? Deposition of collagen, which
is the hallmark of hepatic fibrosis, could be the key driver.
4 Is non-traditional fibrin(ogen) deposition the hallmark
of all types of liver injury? Fibrin(ogen) has been found
in many experimental settings of chronic or acute liver
injury. However, the mechanisms by which fibrin(ogen)
is deposited may be different. For example, in acetami-
nophen-induced acute liver injury, in which no deposi-
tion of collagen occurs, there is massive intrahepatic
crosslinked fibrin deposition, which appears not to
affect injury, but does facilitate repair [13]. In a model
of cholestatic acute liver injury, however, fibrin(ogen)
deposits occur and appear to accelerate injury [14]. Is
this because the types of clot differ between these mod-
els? Also, in a model of fatty liver disease, crosslinked
fibrin(ogen) deposits have been identified in the liver
and adipose tissue [15], and again it would be of inter-
est to identify the make-up of these deposits.
5 Is parenchymal extinction, i.e. the progression of liver
injury by intrahepatic microthrombi, not a relevant
pathological mechanism at all, or does this depend on
the nature, extent and phase of liver injury? The obser-
vation that fibrinogen knockout is protective against
acute biliary injury induced by the hepatotoxicant
a-naphthylisothiocyanate suggests that parenchymal
extinction may be relevant in some forms of liver injury
[14]. A role of fibrin in many other models has been
suggested, but evidence has always been circumstantial,
and it has been suggested that fibrin(ogen) deposition
primarily acts as an innocent bystander [12]. Perhaps a
systematic screen of various clinically relevant liver
injury models in the fibrinogen knockout or fibrinogen
AEK mouse would be of interest.
6 Are these non-traditional clots formed elsewhere? If
collagen is the initiator of non-traditional fibrin(ogen)
deposition, these clots may be formed in fibrotic lesions
in other organs. Models of cardiac [16], pulmonary [17]
and renal fibrosis [18], for example, are known to be
accompanied by fibrin(ogen) deposition, and it would
be of interest to assess the requirement for fibrinogen
cleavage by thrombin, and crosslinking by FXIIIa, in
these models. Could non-traditional clots be formed
intravascularly? Portal vein thrombosis is a poorly
understood, but common, complication of chronic liver
disease that is frequently resistant to anticoagulant
therapy [19]. It is tempting to speculate that (some)
portal vein thrombi are non-traditional clots, which will
be, by definition, unresponsive to anticoagulants.
Although TG2 is thought to be absent from plasma
under normal conditions, it is present in red blood
cells, and TG2 could contribute to fibrin(ogen)
crosslinking in localized or systemic thrombotic diseases.
A contribution of TG2 to clot crosslinking, particularly
under hemolytic conditions, was suggested in the late
1980s [20], but this concept has never been extensively
validated. Thrombotic conditions accompanied by
hemolysis, including sickle cell disease, disseminated
intravascular coagulation, thrombotic microangiopa-
thies such as thrombotic thrombocytopenic purpura,
hemolytic–uremic syndrome, and HELLP syndrome, are
all difficult-to-treat conditions characterized by deposi-
tion of fibrin within organs. It is not inconceivable that
some of these fibrin clots are, in fact, the non-traditional
fibrinogen deposits identified by Poole et al.
Thus, it is of interest to establish whether these ‘non-
traditional’ clots are specific for liver diseases or clinical
conditions in which intrahepatic fibrin deposition occurs,
or whether they represent a more widespread phe-
nomenon, perhaps even contributing to intravascular
thrombosis. Next, it will be of interest to ascertain
whether there are situations in which these non-traditional
clots do harm. In the current study, the non-traditional
clots appeared to be true innocent bystanders, as progres-
sion of liver injury was identical between wild-type and
TG2 knockout mice. However, the authors’ conclusion
that ‘these studies provide strong experimental evidence
that the mechanism connecting coagulation activity to liver
fibrosis occurs via a pathway independent of hepatic fibrin
(ogen) deposition in the chronically damaged liver’ may be
premature, as the role of these clots may be context-depen-
dent [12]. Also, it is possible that intrahepatic clots do not
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drive progression of disease, but do affect complications of
chronic liver disease, notably portal hypertension. A recent
study demonstrated relief of portal hypertension by
rivaroxaban in carbon tetrachloride-treated rats [21]. This
effect was proposed to be multifactorial, with reduced
intrahepatic microthrombosis as one of the contributing
mechanisms. Even if intrahepatic thrombosis proves not to
significantly contribute to the progression of liver diseases,
exploration of a functional role of non-traditional fibrino-
gen clots in other settings, notably intravascular thrombo-
sis, remains of interest.
Should there be situations in which TG2-crosslinked
fibrinogen has a functional role, an interesting question
will be whether TG2 is a viable target for pharmacologi-
cal interventions. TG2 has multiple functions, not only as
a transglutaminase, but also as a G-protein for several
seven transmembrane receptors and as a coreceptor for b1
and b3 integrins, and has been implicated in a wide vari-
ety of diseases [7]. Nevertheless, small-molecule inhibitors
of TG2 have been developed, and one of these is under-
going early clinical studies, specifically for patients with
celiac disease (EudraCT Number: 2017-002241-30).
Whether the inhibition of alternative functions of TG2
disqualifies TG2 inhibitors as agents to prevent intravas-
cular or extravascular ‘non-traditional’ fibrin(ogen) depo-
sition would be an important area of investigation.
In summary, the study by Poole et al. has provided
solid evidence against a role of intrahepatic fibrin deposi-
tion in the progression of disease, at least in the chronic
carbon tetrachloride model. During the study of the role
of fibrin deposition in driving liver injury, the authors
have detailed a thrombin-independent and FXIII-inde-
pendent way in which fibrinogen can be deposited and
crosslinked, at least within the liver. Whether this obser-
vation has wider implications remains to be investigated,
but it is certainly an attractive hypothesis.
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